Directly observed therapy for chronic hepatitis C: A randomized clinical trial in the prison setting

2014 ◽  
Vol 37 (8) ◽  
pp. 443-451 ◽  
Author(s):  
Pablo Saiz de la Hoya ◽  
Joaquín Portilla ◽  
Andrés Marco ◽  
Julio García-Guerrero ◽  
Inmaculada Faraco ◽  
...  
Author(s):  
Chidiebere Uchenna Iheka ◽  
Justice Obinna Osuoha ◽  
Idongesit Ekong Archibong ◽  
Peter Uchenna Amadi ◽  
Oluwatoyin Taiwo Adeoti

Variations in liver metabolism as a result of hepatitis C virus have been established by numerous clinical trials. The use of antioxidants supplements has been reported to minimize the implication of this disease. In this regard, we examined the suitability of Solanum fruit juice, a natural source of vitamin C and citrus flavoniod as a precursor for the treatment of patients with chronic hepatitis C. Forty adult patients who were diagnosed with chronic hepatitis C and were under antiviral therapy were divided into two equal groups. Group 1 patients received their antiviral therapy with normal food and water and served as the control group while patients in group 2 were supplemented with Solanum fruit juice for eight consecutive weeks. Measurements for Anthropometric data, C reactive protein (CRP), atherogenic indices, biochemical parameters and activities of liver marker enzymes were recorded before and after eight weeks. No alterations were found in waist circumference, body mass and body fat following regular use of Solanum fruit juice. The serum levels of oxidative stress markers, LDL-cholesterol, total cholesterol, CRP and atherogenic indices decreased in the Solanum fruit juice group when compared to the control group. Moreover, the activities of the liver marker enzyme AST decreased in those who had high levels before the intervention. These results underscore the benefits of Solanum fruit juice in the diet of patients with HCV as a result of decreased cholesterol in blood serum, decreased inflammation, and increase in antioxidant capacity as well as maintaining body mass index. This clinical trial is registered at Pan African Clinical Trial Registry (www.pactr.org) with unique identification number PACTR201802003092138.


Sign in / Sign up

Export Citation Format

Share Document